Anti-Obesity Phentermine-Topiramate Extended Release Pharmacotherapy vs Placebo Among Patients Using a Wearable Activity Tracker

PHASE4CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

June 3, 2020

Primary Completion Date

June 13, 2022

Study Completion Date

October 11, 2022

Conditions
Obesity
Interventions
DRUG

Phentermine-Topiramate Extended Release

Dosing of 3.75/23 mg daily for 15 days, increased to 7.5/46 mg daily

DRUG

Placebo

Placebo looks exactly like the study drug, but it contains no active ingredient

OTHER

Online support system

VitalCare (VitalTech Affiliates LLC) is a digital health platform that allows remote collection of date from the wearable tracker and digital wellness devices used as part of this study. It also will allow subjects to document study medication compliance and will allow the remote visits to be conducted through a video conference between subjects and appropriate study team members.

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT04408586 - Anti-Obesity Phentermine-Topiramate Extended Release Pharmacotherapy vs Placebo Among Patients Using a Wearable Activity Tracker | Biotech Hunter | Biotech Hunter